Elvitegravir (Vitekta)

Elvitegravir (Vitekta) belongs to the class of antiretroviral drugs known as integrase inhibitors. The drug works against HIV's integrase protein, blocking its ability to integrate its genetic code into human cells.

It was given marketing approval in Europe in November 2013. Vitekta is approved for use in combination with a ritonavir-boosted protease inhibitor. Elvitegravir must be dosed in combination with a boosting agent, either low-dose ritonavir or cobicistat.

Elvitegravir is also available as part of the combination products Stribild (combined with tenofovir disoproxil, emtricitabine and cobicistat) and Genvoya (combined with tenofovir alafenamide, emtricitabine and cobicistat).

Vitekta is formulated as a green, pentagon-shaped, 85mg tablet and as a green triangle-shaped 150mg tablet. The dose of elvitegravir is 85mg (one pentagon tablet) once a day if taken with atazanavir/ritonavir or lopinavir/ritonavir, or 150mg (one triangle tablet) once a day if taken with darunavir/ritonavir or fosamprenavir/ritonavir. It should be taken with food.

Vitekta contains lactose, so it is important for your prescribing doctor to know if you are lactose intolerant.

Common side-effects experienced by people taking elvitegravir include: stomach pain, vomiting, rashes, headache, diarrhoea, nausea, tiredness.

Rare side-effects include: depression, suicidal thoughts, insomnia, problems with digestion (dyspepsia), feeling bloated, flatulence, dizziness, tingling, sleepiness, abnormal taste.

It is very important to tell your prescribing doctor about any drugs you are taking, whether they are prescribed by another doctor, bought from a pharmacy, or herbal, recreational, or other drugs. Do not take with carbamazepine, phenobarbital or phenytoin (drugs used to treat epilepsy), rifampicin, St John’s wort, or the boosting agent cobicistat. Elvitegravir also interacts with other drugs, so it is important to tell your doctor about any other drugs you are taking, including rifabutin, warfarin, hormonal contraceptives, bosentan, antacids or multivitamins.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.